1. Antimicrobial resistance in colonizing group B Streptococcus among pregnant women from a hospital in Vietnam.
- Author
-
Van Du V, Dung PT, Toan NL, Van Mao C, Bac NT, Van Tong H, Son HA, Thuan ND, and Viet NT
- Subjects
- Adult, Anti-Bacterial Agents pharmacology, Female, Humans, Middle Aged, Pregnancy, Pregnancy Complications, Infectious epidemiology, Pregnancy Complications, Infectious microbiology, Streptococcal Infections epidemiology, Streptococcal Infections microbiology, Vietnam epidemiology, Young Adult, Anti-Bacterial Agents therapeutic use, Drug Resistance, Bacterial, Pregnancy Complications, Infectious drug therapy, Streptococcal Infections drug therapy, Streptococcus agalactiae drug effects
- Abstract
Few studies have been conducted on group B Streptococcus (GBS) in Vietnam. We determined the GBS colonization and antimicrobial resistance vaginal-rectal profile of 3863 Vietnamese pregnant women over 5 years. Maternal GBS colonization was characterized by antibiotic susceptibility. Overall, the GBS colonization rate was 8.02% (95% CI: 7.20-8.94%). Compared to sampling ≥ 35 weeks of gestation, the GBS colonization rate was statistically higher (p = 0.004) with sampling < 35 weeks. Among 272 antimicrobial susceptibility testing isolates, all were susceptible to ampicillin, penicillin, ceftriaxone, cefotaxime, vancomycin, and quinupristin/dalfopristin. Resistance was highest for tetracycline (89.66%), followed by erythromycin (76.23%) and clindamycin (58.21%). Multidrug resistance and resistance to ≥ 6 different antibiotics were 60.66% and 8.82%, respectively. Resistance to clindamycin but not erythromycin (L phenotype) was 2.2%. The clindamycin resistance rate was significantly increased (p = 0.005) during the study period. These data demonstrate a low rate of maternal GBS colonization. The high rate of erythromycin, clindamycin, and multidrug resistance to GBS that can be transmitted to neonates is an important risk factor to consider. β-lactams continue to be appropriate for first-line treatment and prophylaxis in the study area. Ongoing monitoring should be considered in the future., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF